CAPR Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. (CAPR) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.55 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.2% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Capricor Therapeutics, Inc.
Capricor Therapeutics Inc is a development stage biopharmaceutical company developing products for the treatment of cardiovascular diseases with a focus on heart failure.
Sector
Healthcare
Industry
Biotechnology